Value proposition

Powering the patient’s immune system to cure cancer

TILT Biotherapeutics Ltd is a clinical stage company working in oncology towards enabling T-cell therapies and immune checkpoint inhibitors with oncolytic viruses.

Embodiments of the technology will be used to enhance tumor infiltrating lymphocytes (TILs), chimeric antigen receptor T cells (CAR T) and immune checkpoint inhibiting antibody therapies.

TILT was founded by Pr. Akseli Hemminki, who has published hundreds of papers in the field and treated almost 300 patients with 10 different oncolytic viruses. In 2013, Pr. Hemminki started his second company, TILT Biotherapeutics Ltd, with a technology based on his past findings in the lab, but more importantly in the clinic. The research conducted by TILT alone or in collaboration with some of world’s leading research groups with synergic technologies has generated very excellent results. The lead candidate is a clinical stage TNFα/IL2 armed oncolytic adenovirus (TILT-123 or Ad5/3-E2F-delta24-hTNFα-IRES-hIL2).

Multiple Phase I clinical trials are ongoing.

For contact: BD (at) tiltbio.com

oncolytic viruses, solid tumors, cancer, immunotherapy, oncoimmunology, T-cell therapy, and Immune checkpoint inhibitors